BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16870044)

  • 41. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
    Bae SI; Lee HS; Kim SH; Kim WH
    Br J Cancer; 2002 Jun; 86(12):1888-92. PubMed ID: 12085181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.
    Girault I; Tozlu S; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Oct; 9(12):4415-22. PubMed ID: 14555514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequent gene hypermethylation in laryngeal cancer cell lines and the resistance to demethylation induction by plant polyphenols.
    Paluszczak J; Krajka-Kuźniak V; Małecka Z; Jarmuż M; Kostrzewska-Poczekaj M; Grenman R; Baer-Dubowska W
    Toxicol In Vitro; 2011 Feb; 25(1):213-21. PubMed ID: 21078381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers.
    Soria JC; Rodriguez M; Liu DD; Lee JJ; Hong WK; Mao L
    Cancer Res; 2002 Jan; 62(2):351-5. PubMed ID: 11809677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
    Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
    Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
    Esteller M; Hamilton SR; Burger PC; Baylin SB; Herman JG
    Cancer Res; 1999 Feb; 59(4):793-7. PubMed ID: 10029064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
    Kwong J; Lo KW; To KF; Teo PM; Johnson PJ; Huang DP
    Clin Cancer Res; 2002 Jan; 8(1):131-7. PubMed ID: 11801549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
    Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
    Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
    Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner.
    Su PF; Huang WL; Wu HT; Wu CH; Liu TY; Kao SY
    Oral Oncol; 2010 Oct; 46(10):734-9. PubMed ID: 20729138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
    Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
    Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.
    Zhang Z; Tan S; Zhang L
    Clin Lung Cancer; 2006 Jul; 8(1):62-5. PubMed ID: 16870048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.
    Toyooka S; Maruyama R; Toyooka KO; McLerran D; Feng Z; Fukuyama Y; Virmani AK; Zochbauer-Muller S; Tsukuda K; Sugio K; Shimizu N; Shimizu K; Lee H; Chen CY; Fong KM; Gilcrease M; Roth JA; Minna JD; Gazdar AF
    Int J Cancer; 2003 Jan; 103(2):153-60. PubMed ID: 12455028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes.
    Su Y; Xu H; Xu Y; Yu J; Xian Y; Luo Q
    Hematology; 2012 Jan; 17(1):41-6. PubMed ID: 22549447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
    Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
    Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.